Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

KALEIDO BIOSCIENCES, INC.

(KLDO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Kaleido Biosciences, Inc. to Host Virtual R&D Presentation to Discuss Clinical Data and Pipeline Advancement on October 5, 2021

09/29/2021 | 07:30am EST

Kaleido Biosciences, Inc. announced that it will host a virtual R&D Presentation on October 5, 2021, at 8 a.m. ET. The agenda will feature an update on the Company’s corporate strategy, data from the non-IND study evaluating KB295 in mild-to-moderate UC as well as supportive preclinical data, and data supporting the advancement of KB109 into COPD. KB295 and KB109 are novel, orally administered Microbiome Metabolic Therapies (MMT™) developed using Kaleido’s proprietary synthetic chemistry technology.


© S&P Capital IQ 2021
All news about KALEIDO BIOSCIENCES, INC.
12/06Kaleido Biosciences Expands and Extends Collaboration With Janssen
MT
12/06Kaleido Biosciences Announces Expansion of Collaboration with Janssen to Explore Potent..
GL
12/06Kaleido Biosciences Announces Expansion of Collaboration with Janssen to Explore Potent..
CI
11/15Kaleido Biosciences to Participate in the Piper Sandler 33rd Annual Virtual Healthcare ..
GL
11/12Chardan Adjusts Price Target on Kaleido Biosciences to $11 From $15 on Pipeline Assets ..
MT
11/10Kaleido Biosciences to Appoint Dr. Alison Long as Chief Medical Officer
GL
11/10Kaleido Biosciences, Inc. to Appoint Alison Long as Chief Medical Officer, Effective De..
CI
11/03JMP Securities Adjusts Price Target on Kaleido Biosciences to $22 From $25, Maintains M..
MT
11/01KALEIDO BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
11/01Press Release issued by Kaleido Biosciences, Inc., dated November 1, 2021, furnished he..
PU
More news
Analyst Recommendations on KALEIDO BIOSCIENCES, INC.
More recommendations
Financials (USD)
Sales 2021 1,61 M - -
Net income 2021 -94,6 M - -
Net cash 2021 5,83 M - -
P/E ratio 2021 -1,60x
Yield 2021 -
Capitalization 153 M 153 M -
EV / Sales 2021 91,8x
EV / Sales 2022 169x
Nbr of Employees 82
Free-Float 91,0%
Chart KALEIDO BIOSCIENCES, INC.
Duration : Period :
Kaleido Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KALEIDO BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 3,60 $
Average target price 14,80 $
Spread / Average Target 311%
EPS Revisions
Managers and Directors
Daniel L. Menichella President, Chief Executive Officer & Director
William E. Duke Chief Financial Officer
Theo Melas-Kyriazi Chairman
Johan van Hylckama Vlieg Chief Scientific Officer
Kimberly Hocknell Senior Vice President-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
KALEIDO BIOSCIENCES, INC.-64.40%153
MODERNA, INC.153.98%107 578
LONZA GROUP AG25.98%56 683
IQVIA HOLDINGS INC.46.84%50 262
SEAGEN INC.-16.63%26 699
CELLTRION, INC.-43.31%23 888